KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Discontinued OperationsCash from Discontinued OperationsCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other financing activities (2018 - 2026)

TherapeuticsMD filings provide 12 years of Other financing activities readings, the most recent being $2000.0 for Q1 2026.

  • On a quarterly basis, Other financing activities fell 91.3% to $2000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $1.4 million, a 372.15% increase, with the full-year FY2023 number at $1.3 million, down 21.64% from a year prior.
  • Other financing activities hit $2000.0 in Q1 2026 for TherapeuticsMD, down from $23000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.3 million in Q4 2023 to a low of -$1.1 million in Q3 2023.
  • Median Other financing activities over the past 5 years was $111000.0 (2024), compared with a mean of $336555.6.
  • The widest YoY moves for Other financing activities: up 42.33% in 2023, down 251.85% in 2023.
  • TherapeuticsMD's Other financing activities stood at $893000.0 in 2022, then skyrocketed by 42.33% to $1.3 million in 2023, then tumbled by 91.27% to $111000.0 in 2024, then tumbled by 79.28% to $23000.0 in 2025, then crashed by 91.3% to $2000.0 in 2026.
  • The last three reported values for Other financing activities were $2000.0 (Q1 2026), $23000.0 (Q1 2025), and $111000.0 (Q1 2024) per Business Quant data.